The world's largest drugmaker thinks it has 11 billion-dollar drugs in the pipeline - here's what they treat
Advertisement
Jonathan Ernst/Reuters
Advertisement
These are drugs that haven't been approved yet, but by 2021, they could be making more than $1 billion in annual sales each.
Right now, the world's largest drugmaker is known for its immunology drugs like Remicade, which made $4.8 billion in sales in 2016 and Stelara, as well as the bloodthinner Xarelto, which made $2.2 billion in sales in 2016.
Here's the list of drugs J&J plans to file for approval over the next four years that could hit that blockbuster threshold, including cancer and depression treatments:
- guselkumab - psoriasis (Filed for approval in 2016)
- sirukumab - rheumatoid arthritis (Filed for approval in 2016)
- apalutamide - pre-metastatic prostate cancer
- esketamine - treatment-resistant depression
- talacotuzumab - acute myeloid leukemia, a type of blood cancer
- erdafitinib - solid tumors
- niraparib - prostate cancer
- imetelstat - myelofibrosis, a bone marrow disorder
- pimodivir - influenza A
- lumicitabine - respiratory syncytial virus (RSV) infection
- JNJ-7922 - adjunctive treatment for major depressive disorder
Advertisement
- BenQ Zowie XL2546X review – Monitor for the serious gamers
- 9 health benefits of drinking sugarcane juice in summer
- 10 benefits of incorporating almond oil into your daily diet
- From heart health to detoxification: 10 reasons to eat beetroot
- Why did a NASA spacecraft suddenly start talking gibberish after more than 45 years of operation? What fixed it?